Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

J.P. Clancy; P. Campbell; I. Bronsveld; M. W. Konstan; et al et al

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Translated title of the contribution: Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

J.P. Clancy, P. Campbell, I. Bronsveld, M. W. Konstan, et al et al

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Original language	Undefined/Unknown
Pages (from-to)	12-18
Number of pages	7
Journal	Thorax
Volume	67
Issue number	1
Publication status	Published - 2012

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/21825083

Cite this

@article{9cad4f74390b4735a1e4d2d0a5c30813,

title = "Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.",

author = "J.P. Clancy and P. Campbell and I. Bronsveld and Konstan, {M. W.} and {et al}, {et al}",

year = "2012",

language = "Undefined/Unknown",

volume = "67",

pages = "12--18",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

AU - Clancy, J.P.

AU - Campbell, P.

AU - Bronsveld, I.

AU - Konstan, M. W.

AU - et al, et al

PY - 2012

Y1 - 2012

M3 - Article

SN - 0040-6376

VL - 67

SP - 12

EP - 18

JO - Thorax

JF - Thorax

IS - 1

ER -